IPCA Laboratories Q1 Results FY26: Q1 PAT Rises 21.31% to ₹233.21 Crore; Revenue Up 10.33% YoY

IPCA Laboratories Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

Particulars	Quarter Ended
	30-06-2025	30-06-2024
Revenue from Operations	₹2,308.85	₹2,092.63
Profit Before Tax (PBT)	₹449.08	₹413.33
Profit After Tax (PAT)	₹233.21	₹192.24

(Figures in crores)

IPCA Laboratories Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

Particulars	Quarter Ended
	30-06-2025	30-06-2024
Revenue from Operations	₹1,746.90	₹1,565.86
Profit Before Tax (PBT)	₹431.94	₹368.63
Profit After Tax (PAT)	₹262.04	₹204.13

(Figures in crores)

IPCA Laboratories Q1 Results FY26 Highlights (Q1 FY26 vs FY25)

• IPCA Laboratories clocked Q1 FY26 consolidated revenue of ₹2,308.85 crores vs ₹2,092.63 crores. 
• On the profit front, IPCA Laboratories earned a consolidated PAT of ₹233.21 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹192.24 crore. 
• Consolidated PAT rose for the first quarter of FY26, was 21.31% YoY, and revenue rose 10.33% YoY. 
• As per the standalone figures, the quarterly PAT of IPCA Laboratories has increased by 28.37%, and revenue has increased by 11.56% YoY.

IPCA Laboratories Share Price Performance

On the opening bell of 11th August 2025, the shares of IPCA Laboratories opened at ₹1,380.00 per share. However, the initial gains are wiped out as of now, and IPCA Laboratories shares are trading at ₹1,336.00 per share, lower than their opening price. 

Considering the long-term performance, IPCA Laboratories shares have yielded close to -3.33% returns in the past 1 year, and 5-year returns stand at 32.72%. Over the maximum timeframe, the IPCA Laboratories share provided 26,889.90% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in IPCA Laboratories shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Icodex Publishing Solutions IPO GMP: Day 1 IPO Live Updates

Bluestone Jewellery IPO GMP: Day 1 IPO Live Updates

Highway Infrastructure IPO Listing Preview: What to Expect Now in 2025?

Concord Biotech Q1 Results FY26: Q1 PAT Falls 26.07% to ₹44.06 Crore; Revenue Down 5.47% YoY

Action Construction Equipment Q1 Results FY26: Q1 PAT Rises 16.08% to ₹97.72 Crore; Revenue Down 11.19% YoY

Sawaliya Foods Products IPO Allotment Status Check Online: GMP, Subscription, Price, and More

JSW Cement IPO Allotment Status Check Online: GMP, Subscription, Price, and More

Mahendra Realtors IPO GMP & Review: Apply or Avoid?

Regaal Resources IPO GMP & Review: Apply or Avoid?

Icodex Publishing Solutions IPO GMP & Review: Apply or Avoid?